Plain-English translation of NCT06530576 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing thalidomide, a medication taken by mouth, to see if it can help people with large granular lymphocytic leukemia—a rare blood disorder where certain immune cells grow out of control. The study will follow patients for up to a year to measure how well the medication works and whether it helps reduce symptoms like low blood counts, infections, and anemia.
Large granular lymphocytic leukemia is rare and currently has limited treatment options. This trial aims to find out whether this medication could be a safer, more effective choice for patients who haven't responded well to other treatments.
You likely qualify if…
You likely don't qualify if…
You will take this medication by mouth every night at a dose of 50–100 mg. Your progress will be checked every 4 months to see how well the treatment is working. Depending on your response, you may continue for up to 12 months total (three 4-month cycles), and your doctor may add another medication if needed. You will have regular blood tests and clinic visits to monitor your health and side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China